These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
426 related articles for article (PubMed ID: 20831354)
1. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors. Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354 [TBL] [Abstract][Full Text] [Related]
2. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Abe Y; Muto M; Nieda M; Nakagawa Y; Nicol A; Kaneko T; Goto S; Yokokawa K; Suzuki K Exp Hematol; 2009 Aug; 37(8):956-68. PubMed ID: 19409955 [TBL] [Abstract][Full Text] [Related]
3. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Dieli F; Vermijlen D; Fulfaro F; Caccamo N; Meraviglia S; Cicero G; Roberts A; Buccheri S; D'Asaro M; Gebbia N; Salerno A; Eberl M; Hayday AC Cancer Res; 2007 Aug; 67(15):7450-7. PubMed ID: 17671215 [TBL] [Abstract][Full Text] [Related]
4. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372 [TBL] [Abstract][Full Text] [Related]
5. Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses. Nussbaumer O; Gruenbacher G; Gander H; Komuczki J; Rahm A; Thurnher M J Immunol; 2013 Aug; 191(3):1346-55. PubMed ID: 23794630 [TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study. Sakamoto M; Nakajima J; Murakawa T; Fukami T; Yoshida Y; Murayama T; Takamoto S; Matsushita H; Kakimi K J Immunother; 2011 Mar; 34(2):202-11. PubMed ID: 21304399 [TBL] [Abstract][Full Text] [Related]
7. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Fiore F; Castella B; Nuschak B; Bertieri R; Mariani S; Bruno B; Pantaleoni F; Foglietta M; Boccadoro M; Massaia M Blood; 2007 Aug; 110(3):921-7. PubMed ID: 17403919 [TBL] [Abstract][Full Text] [Related]
8. Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation. Takahara M; Miyai M; Tomiyama M; Mutou M; Nicol AJ; Nieda M J Leukoc Biol; 2008 Mar; 83(3):742-54. PubMed ID: 18156189 [TBL] [Abstract][Full Text] [Related]
9. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953 [TBL] [Abstract][Full Text] [Related]
10. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate. Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685 [TBL] [Abstract][Full Text] [Related]
11. Expansion of human peripheral blood γδ T cells using zoledronate. Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292 [TBL] [Abstract][Full Text] [Related]
12. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma]. Li Z; Tang J; Sun L; Ye Z Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710 [TBL] [Abstract][Full Text] [Related]
13. [Amplification of γδ T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate]. Li ZX; Sun LL; Cheng RL; Sun ZW; Ye ZM Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Aug; 28(8):822-4. PubMed ID: 22863589 [TBL] [Abstract][Full Text] [Related]
14. The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients. Ebina T; Fujimiya Y; Yamaguchi T; Ogama N; Sasaki H; Isono N; Suzuki Y; Katakura R; Tanaka K; Nagata K; Takano S; Tamura K; Uno K; Kishida T Biotherapy; 1998; 11(4):241-53. PubMed ID: 9950100 [TBL] [Abstract][Full Text] [Related]
15. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. Lang JM; Kaikobad MR; Wallace M; Staab MJ; Horvath DL; Wilding G; Liu G; Eickhoff JC; McNeel DG; Malkovsky M Cancer Immunol Immunother; 2011 Oct; 60(10):1447-60. PubMed ID: 21647691 [TBL] [Abstract][Full Text] [Related]
16. Cellular interactions of synovial fluid γδ T cells in juvenile idiopathic arthritis. Bendersky A; Marcu-Malina V; Berkun Y; Gerstein M; Nagar M; Goldstein I; Padeh S; Bank I J Immunol; 2012 May; 188(9):4349-59. PubMed ID: 22450805 [TBL] [Abstract][Full Text] [Related]
17. TCRVγ9 γδ T Cell Response to IL-33: A CD4 T Cell-Dependent Mechanism. Duault C; Franchini DM; Familliades J; Cayrol C; Roga S; Girard JP; Fournié JJ; Poupot M J Immunol; 2016 Jan; 196(1):493-502. PubMed ID: 26608919 [TBL] [Abstract][Full Text] [Related]
18. Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer. Caccamo N; Meraviglia S; Cicero G; Gulotta G; Moschella F; Cordova A; Gulotta E; Salerno A; Dieli F Curr Med Chem; 2008; 15(12):1147-53. PubMed ID: 18473809 [TBL] [Abstract][Full Text] [Related]
19. γδ T cell activation by bispecific antibodies. Oberg HH; Kellner C; Gonnermann D; Peipp M; Peters C; Sebens S; Kabelitz D; Wesch D Cell Immunol; 2015 Jul; 296(1):41-9. PubMed ID: 25979810 [TBL] [Abstract][Full Text] [Related]
20. In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study. Pressey JG; Adams J; Harkins L; Kelly D; You Z; Lamb LS Medicine (Baltimore); 2016 Sep; 95(39):e4909. PubMed ID: 27684826 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]